1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 4:Diagnostic accuracies for parent artery patency of NC-MRA for each separate device, for patients treated with FD exclusively and those treated with additional device
Pipeline Shield (n = 28) Surpass Evolve (n = 19) Silk Vista Baby (n = 9) FD Exclusively (n = 22) Additional Device (n = 34) Specificity (95% CI) 0.96 (0.78–1.00) 0.57 (0.29–0.82) 1 (0.48–1.00) 0.87 (0.60–0.98) 0.81 (0.62–0.94) PPV (95% CI) 0.80 (0.28–0.99) 0.45 (0.17–0.77) 1 (0.40–1.00) 0.78 (0.40–0.97) 0.55 (0.23–0.83) Sensitivity (95% CI) 0.80 (0.28–0.99) 1 (0.48–1.00) 1 (0.40–1.00) 1 (0.59–1.00) 0.86 (0.42–1.00) NPV (95% CI) 0.96 (0.78–1.00) 1 (0.63–1.00) 1 (0.48–1.00) 1 (0.75–1.00) 0.96 (0.78–1.00)